Summary: Retatrutide is an investigational weight loss peptide and triple receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly that has not yet received MHRA or EMA marketing authorisation and remains unavailable through NHS or regulated UK prescribing pathways
Increases metabolism to burn fat Both GIP and glucagon help your body burn energy, rather than storing it as fat
GLP-1 weight-loss drugs are cutting calories and grocery bills, according to a new study from Cornells SC Johnson College of Business using data from Numerator
That might mean timing your dose before departure, securing hotel refrigeration at each stop, or using a plug-in travel cooler
Nogueiras R, Nauck MA, Tschop MH
However, real-world experience and the pharmacokinetic principles of volume of distribution suggest that lighter individuals benefit from a more conservative start, while heavier individuals may tolerate a slightly more aggressive approach